UCL School of Pharmacy


Five School of Pharmacy academics and PhD researchers listed as influential researchers

28 November 2022

Professors Abdul Basit, Simon Gaisford and Drs Alvaro Goyanes, Atheer Awad and Sarah Trenfield, academics and PhD researchers, have been identified as “one in 1,000 Citation Elite” on Clarivate’s annual ‘Highly Cited Researchers List’ 2022.

Since 2001, the Highly Cited Researchers™ list has identified global research scientists and social scientists who have demonstrated exceptional influence in their field, reflected through publications of multiple papers frequently cited by their peers during the last decade. 

The names are drawn from the publications that rank in the top 1% by citations for field and publication year in the Web of Science citation index, with the list also used to identify the research institutions and countries where the citation elite are based. 

This list identifies and celebrates exceptional individual researchers at UCL who are having a significant impact on the research community as evidenced by the rate at which their work is being cited by their peers. The research they have contributed is fuelling innovation within pharmaceutical research and the life sciences. 

The text has a dark background with the name Clarivate and the text Highly Cited Researchers 2022.

In 2022, fewer than 0.1% of the world’s researchers across 21 research fields have earned this exclusive distinction. Recognised for their exceptional research influence, Professor Abdul Basit, Professor Simon Gaisford and Dr Alvaro Goyanes of the UCL School of Pharmacy have received the honour of being Highly Cited Researchers for a fourth year in a row. Excitingly, Dr. Sarah Trenfield and Dr. Atheer Awad, young researchers who are pioneers in the three-dimensional printing of medicines joined the Highly Cited 2022 list. It is a remarkable achievement for young scientists to appear on this prestigious list. 
Professor Abdul Basit shared “Congratulations to all PhD researchers, post-docs, collaborators and spin out companies that have contributed to achieve this. Let us all continue to aim towards translational and cutting-edge research to deliver improved therapies for patients.”

Further information